It doesn't seem long ago that Glaxo was being criticised for numerous failings as it was put in the shade by arch rival AstraZeneca. Things have changed, so Alistair Strang gives his view on possible next moves.
It is interesting that GlaxoSmithKline's (LSE:GSK) share price appears to be on the verge of becoming useful, almost at the point of challenging the pre-pandemic highs of 2020.
This is creating a fascinating scenario as now above 1,817p suggests imminent moves to an initial 1,841p. In the event such a level is exceeded, quite likely with the price trading around 1,798p at time of writing, our secondary works out at 1,870p and a new all-time high.
Quite coyly, we’ve chosen to show a longer-term 2,009p on the chart below as a viable long-term ambition, representing a level at which we’d suspect some hesitation.
For everything to go horribly wrong, Glaxo needs below 1,700p as this calculates with the threat of reversal to an initial 1,625p. At such a level, we’d hope for a bounce as our secondary works out at an uptrend breaking 1,406p.
At present, we’re inclined toward optimism for this share price.
Source: Trends and Targets. Past performance is not a guide to future performance
Alistair Strang has led high-profile and "top secret" software projects since the late 1970s and won the original John Logie Baird Award for inventors and innovators. After the financial crash, he wanted to know "how it worked" with a view to mimicking existing trading formulas and predicting what was coming next. His results speak for themselves as he continually refines the methodology.
Alistair Strang is a freelance contributor and not a direct employee of Interactive Investor. All correspondence is with Alistair Strang, who for these purposes is deemed a third-party supplier. Buying, selling and investing in shares is not without risk. Market and company movement will affect your performance and you may get back less than you invest. Neither Alistair Strang or Interactive Investor will be responsible for any losses that may be incurred as a result of following a trading idea.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.